<?xml version='1.0' encoding='utf-8'?>
<document id="25942458"><sentence text="Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers."><entity charOffset="52-63" id="DDI-PubMed.25942458.s1.e0" text="Raltegravir" /><entity charOffset="68-80" id="DDI-PubMed.25942458.s1.e1" text="Atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25942458.s1.e0" e2="DDI-PubMed.25942458.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s1.e0" e2="DDI-PubMed.25942458.s1.e1" /></sentence><sentence text="Dyslipidemia is highly prevalent among patients with HIV infection and contributes to an increased risk of cardiovascular disease" /><sentence text=" We investigated the influence of a frequently used statin, atorvastatin, on the pharmacokinetics of the HIV-integrase inhibitor raltegravir and vice versa"><entity charOffset="60-72" id="DDI-PubMed.25942458.s3.e0" text="atorvastatin" /></sentence><sentence text="" /><sentence text="Open-label, crossover 3-period phase I trial in 24 healthy volunteers" /><sentence text=" Subjects took raltegravir 400 mg two times a day for 7 days, atorvastatin 20 mg once a day for 7 days, and the combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days with 2-week washout periods in between"><entity charOffset="62-74" id="DDI-PubMed.25942458.s6.e0" text="atorvastatin" /><entity charOffset="127-139" id="DDI-PubMed.25942458.s6.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25942458.s6.e0" e2="DDI-PubMed.25942458.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s6.e0" e2="DDI-PubMed.25942458.s6.e1" /></sentence><sentence text=" Intensive steady-state 12- and 24-hour pharmacokinetic blood sampling was performed" /><sentence text=" Geometric mean ratios of the test treatment (combination raltegravir + atorvastatin) versus the reference treatment (raltegravir or atorvastatin alone) and 90% confidence intervals were calculated for the area under the plasma concentration-time curve (AUC)"><entity charOffset="58-84" id="DDI-PubMed.25942458.s8.e0" text="raltegravir + atorvastatin" /><entity charOffset="133-145" id="DDI-PubMed.25942458.s8.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25942458.s8.e0" e2="DDI-PubMed.25942458.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s8.e0" e2="DDI-PubMed.25942458.s8.e1" /></sentence><sentence text=" Fasting lipid profiles were obtained to assess short-term lipid-lowering effect of atorvastatin with or without concomitant raltegravir use"><entity charOffset="84-96" id="DDI-PubMed.25942458.s9.e0" text="atorvastatin" /><entity charOffset="125-136" id="DDI-PubMed.25942458.s9.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.25942458.s9.e0" e2="DDI-PubMed.25942458.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s9.e0" e2="DDI-PubMed.25942458.s9.e1" /></sentence><sentence text="" /><sentence text="Twenty-four healthy volunteers (11 males) were enrolled" /><sentence text=" All but 1 subject completed the trial, and no serious adverse events were reported" /><sentence text=" Geometric mean ratios (90% confidence interval) were 1" /><sentence text="01 (0" /><sentence text="68-1" /><sentence text="51) for raltegravir AUC(0-12h) and 1" /><sentence text="00 (0" /><sentence text="90-1" /><sentence text="11) for atorvastatin AUC(0-24h)"><entity charOffset="8-31" id="DDI-PubMed.25942458.s19.e0" text="atorvastatin AUC(0-24h)" /></sentence><sentence text=" The AUC(0-24h) metabolite-to-parent ratio for atorvastatin lactone, ortho-hydroxy, and para-hydroxy atorvastatin did not change during concomitant raltegravir use"><entity charOffset="5-15" id="DDI-PubMed.25942458.s20.e0" text="AUC(0-24h)" /><entity charOffset="47-67" id="DDI-PubMed.25942458.s20.e1" text="atorvastatin lactone" /><entity charOffset="69-82" id="DDI-PubMed.25942458.s20.e2" text="ortho-hydroxy" /><entity charOffset="88-113" id="DDI-PubMed.25942458.s20.e3" text="para-hydroxy atorvastatin" /><entity charOffset="148-159" id="DDI-PubMed.25942458.s20.e4" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e0" e2="DDI-PubMed.25942458.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e0" e2="DDI-PubMed.25942458.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e0" e2="DDI-PubMed.25942458.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e0" e2="DDI-PubMed.25942458.s20.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e0" e2="DDI-PubMed.25942458.s20.e4" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e1" e2="DDI-PubMed.25942458.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e1" e2="DDI-PubMed.25942458.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e1" e2="DDI-PubMed.25942458.s20.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e1" e2="DDI-PubMed.25942458.s20.e4" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e2" e2="DDI-PubMed.25942458.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e2" e2="DDI-PubMed.25942458.s20.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e2" e2="DDI-PubMed.25942458.s20.e4" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e3" e2="DDI-PubMed.25942458.s20.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s20.e3" e2="DDI-PubMed.25942458.s20.e4" /></sentence><sentence text=" The effect of atorvastatin on low-density lipoprotein cholesterol was not significantly different when combined with raltegravir versus atorvastatin alone (P = 0"><entity charOffset="15-27" id="DDI-PubMed.25942458.s21.e0" text="atorvastatin" /><entity charOffset="55-66" id="DDI-PubMed.25942458.s21.e1" text="cholesterol" /><entity charOffset="118-129" id="DDI-PubMed.25942458.s21.e2" text="raltegravir" /><entity charOffset="137-149" id="DDI-PubMed.25942458.s21.e3" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e0" e2="DDI-PubMed.25942458.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e0" e2="DDI-PubMed.25942458.s21.e1" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e0" e2="DDI-PubMed.25942458.s21.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e0" e2="DDI-PubMed.25942458.s21.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e1" e2="DDI-PubMed.25942458.s21.e1" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e1" e2="DDI-PubMed.25942458.s21.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e1" e2="DDI-PubMed.25942458.s21.e3" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e2" e2="DDI-PubMed.25942458.s21.e2" /><pair ddi="false" e1="DDI-PubMed.25942458.s21.e2" e2="DDI-PubMed.25942458.s21.e3" /></sentence><sentence text="638)" /><sentence text="" /><sentence text="Atorvastatin 20 mg has no clinically relevant effect on the pharmacokinetics of raltegravir and vice versa"><entity charOffset="0-12" id="DDI-PubMed.25942458.s24.e0" text="Atorvastatin" /><entity charOffset="80-91" id="DDI-PubMed.25942458.s24.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.25942458.s24.e0" e2="DDI-PubMed.25942458.s24.e0" /><pair ddi="false" e1="DDI-PubMed.25942458.s24.e0" e2="DDI-PubMed.25942458.s24.e1" /></sentence><sentence text=" The combination was well tolerated and can be administered without dose adjustments" /><sentence text="" /></document>